Tarsus Pharmaceuticals Stock Analysis
| TARS Stock | USD 39.18 1.98 4.81% |
Tarsus Pharmaceuticals is overvalued with Real Value of 35.58 and Hype Value of 39.18. The main objective of Tarsus Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Tarsus Pharmaceuticals is worth, separate from its market price. There are two main types of Tarsus Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Tarsus Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tarsus Pharmaceuticals is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Tarsus Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. Tarsus Stock Analysis Notes
About 97.0% of the company shares are owned by institutional investors. The book value of Tarsus Pharmaceuticals was at this time reported as 8.15. The company has Price/Earnings To Growth (PEG) ratio of 0.28. Tarsus Pharmaceuticals recorded a loss per share of 2.7. The entity had not issued any dividends in recent years. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people. To find out more about Tarsus Pharmaceuticals contact the company at 949 409 1801 or learn more at https://www.tarsusrx.com.Tarsus Pharmaceuticals Investment Alerts
| Tarsus Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 182.95 M. Net Loss for the year was (115.55 M) with profit before overhead, payroll, taxes, and interest of 161.56 M. | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (83.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Over 97.0% of the company shares are owned by institutional investors |
Tarsus Pharmaceuticals Upcoming and Recent Events
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Tarsus Pharmaceuticals Thematic Classifications
In addition to having Tarsus Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | BiotechBiotechnology and pharmaceuticals production and services |
Tarsus Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.65 B.Tarsus Profitablity
The company has Profit Margin (PM) of (0.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.34) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.34.Technical Drivers
As of the 13th of July 2025, Tarsus Pharmaceuticals has the Coefficient Of Variation of (741.91), risk adjusted performance of (0.18), and Variance of 5.72. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tarsus Pharmaceuticals, as well as the relationship between them. Please validate Tarsus Pharmaceuticals risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Tarsus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 39.18 per share. Given that Tarsus Pharmaceuticals has information ratio of (0.24), we advise you to double-check Tarsus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.Tarsus Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tarsus Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tarsus Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Tarsus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tarsus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tarsus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tarsus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tarsus Pharmaceuticals Outstanding Bonds
Tarsus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tarsus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tarsus bonds can be classified according to their maturity, which is the date when Tarsus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Tarsus Pharmaceuticals Predictive Daily Indicators
Tarsus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tarsus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tarsus Pharmaceuticals Forecast Models
Tarsus Pharmaceuticals' time-series forecasting models are one of many Tarsus Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tarsus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Tarsus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Tarsus Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tarsus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tarsus Pharmaceuticals. By using and applying Tarsus Stock analysis, traders can create a robust methodology for identifying Tarsus entry and exit points for their positions.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Tarsus Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.